What Is an Eylea Injection?

An Eylea injection contains aflibercept, a medication specifically designed to treat certain eye conditions by blocking vascular endothelial growth factor (VEGF). VEGF is a protein that promotes the growth of abnormal blood vessels in the retina that can leak fluid and blood, damaging vision. By inhibiting VEGF, Eylea helps reduce this abnormal growth and leakage, potentially preserving and sometimes improving vision.

Developed by Regeneron Pharmaceuticals, Eylea is FDA-approved for treating several conditions including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy, and macular edema following retinal vein occlusion. The medication is administered directly into the eye through a very fine needle in a procedure called an intravitreal injection.

The Eylea Injection Procedure

The eylea injection procedure is typically performed in an ophthalmologist's office and takes only a few minutes. First, your eye will be numbed with anesthetic drops to minimize discomfort. The doctor will clean the eye area with an antiseptic solution to prevent infection. A small device called a speculum may be placed to keep your eyelids open during the procedure.

The actual injection is very quick—just a few seconds. Most patients report feeling pressure rather than pain. After the injection, your doctor might prescribe antibiotic eye drops to prevent infection. The entire appointment usually takes less than an hour, with most of that time being preparation and post-injection monitoring. Eylea injection recovery time is relatively short, with most patients able to resume normal activities the same day, though you should avoid swimming or exposing your eye to dust for at least 24 hours.

Eylea for Macular Degeneration

Eylea injection for macular degeneration has become a standard treatment option for the wet form of this condition. Clinical studies have shown that Eylea can help maintain vision in over 95% of patients with wet AMD and improve vision in about one-third of patients when administered regularly. The typical treatment schedule begins with monthly injections for three months, followed by injections every 8-12 weeks, though this varies based on individual response.

What makes Eylea particularly valuable for macular degeneration patients is its ability to not just slow vision loss but potentially restore some vision that has been compromised by the disease. The effectiveness of the treatment depends on how early the condition is caught and treatment begins. Regular eye examinations are crucial for early detection, especially for those with risk factors for macular degeneration such as family history, smoking, or being over 60 years old.

Comparing Eylea to Other Treatments

When considering treatment options, many patients and doctors compare Eylea vs Lucentis (ranibizumab) and other anti-VEGF medications. While all these treatments work by inhibiting VEGF, they differ in molecular structure, dosing schedule, and sometimes in cost and insurance coverage.

Here's how these treatments compare:

  • Eylea (aflibercept): Often administered every 8-12 weeks after initial monthly doses. Clinical trials show comparable or slightly better results for some conditions compared to other treatments. Manufactured by Regeneron Pharmaceuticals.
  • Lucentis (ranibizumab): Typically given monthly, though some patients may qualify for less frequent dosing. Has a long track record of safety and efficacy. Produced by Genentech.
  • Avastin (bevacizumab): Used off-label for eye conditions, generally administered monthly. Often less expensive than other options. Also made by Genentech.
  • Beovu (brolucizumab): A newer option that may allow for 12-week dosing intervals after loading doses. Manufactured by Novartis.

Your ophthalmologist will recommend the best option based on your specific condition, response to treatment, and other factors including insurance coverage and cost considerations.

Side Effects and Cost Considerations

Like all medical treatments, eylea injection side effects can occur. The most common include:

  • Eye redness or irritation
  • Seeing floating spots (floaters)
  • Increased pressure in the eye (usually temporary)
  • Feeling like something is in your eye

More serious but rare complications include eye infection, retinal detachment, and inflammation inside the eye. It's important to contact your doctor immediately if you experience severe eye pain, vision changes, or increased sensitivity to light after an injection.

Regarding finances, eylea injection cost can be significant. Without insurance, the eylea injection price ranges from $1,800 to $2,000 per injection. However, most insurance plans, including Medicare, cover these treatments for approved conditions. Regeneron, the manufacturer, offers a patient assistance program for those who qualify. When considering eylea eye injection reviews, most patients report that the benefits to their vision outweigh both the discomfort of the procedure and the cost considerations.

Conclusion

Eylea injections represent an important advancement in treating serious eye conditions that once inevitably led to vision loss. While the idea of an eye injection may seem intimidating, the procedure is quick and relatively comfortable for most patients. If you're considering this treatment, discuss all aspects with your ophthalmologist, including frequency of treatments, expected outcomes, and financial considerations. Finding an eylea injection near me is typically as simple as asking for a referral to a retina specialist from your regular eye doctor. With proper treatment and follow-up care, many patients maintain their vision and independence for years after diagnosis.

Citations

This content was written by AI and reviewed by a human for quality and compliance.